The Cambridge-based drug maker said the deal settles "all worldwide" litigation related to certain drugs and it won't have to pay royalties to other companies.

COVID-19 vaccination showed effectiveness in reducing hospitalizations and severe disease outcomes associated with the SARS-CoV-2 JN.1 lineage, according to a recent study published in JAMA Network ...

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.

CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...

CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine remained 93% effective against symptomatic illness six months after the second dose, but amid the ongoing spread of the highly contagious delta variant, ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million ...

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for ...

The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies that neutralize the intended SARS-CoV-2 variant target among recipients, according to a press release from ...

NAIROBI, Kenya - Moderna on Tuesday said it will make up to 110 million doses of its COVID-19 vaccine available to African countries, which local officials called a breakthrough on the world's least ...